Seasonal allergic rhinitis
Drug research and approvals for seasonal allergic rhinitis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 19 studies of seasonal allergic rhinitis are recruiting on ClinicalTrials.gov, Health Canada has authorized 15 drug trials for it since 2013, and the EU has 1 authorised medicine for it.
- Recruiting worldwide: 19
- Trials authorized in Canada: 15
- FDA orphan approvals: 0
- EU medicines: 1
- Safety, Tolerability And Pharmacodynamics of DM-101PX in Birch Pollen AllergyNCT07898800 · Phase 1 · Desentum Oy · starts Oct 29, 2026
- Investigating Nasal and Ocular Immune Response to Conjunctival Allergen ExposureNCT07801625 · Not reported · Dr. Anne Ellis · starts Sep 1, 2026
- Phase 1, First in Human (FIH), Open-Label, Single-Arm, Ascending Dose Study to Assess the Safety, Tolerability and…NCT07726147 · Phase 1 · Immunomic Therapeutics, Inc. · starts Jun 20, 2026
- Rupatifen Fumarate Capsules in Patients With Seasonal Allergic RhinitisNCT07711262 · Phase 3 · Fujian Mindong Rejuvenation Pharmaceutical Co., Ltd. · starts Aug 18, 2026
- Study on the Treatment of Adolescent Patients With Seasonal Allergic RhinitisNCT07678931 · Phase 3 · Chengdu Kangnuoxing Biopharma,Inc. · starts Aug 13, 2026
- Evaluation of the Efficacy, Safety, and Tolerability of PL-14 Allergy Blocker Compared to Saline Spray in Patients With…NCT07588672 · Not applicable · Polyrizon Ltd. · starts Sep 1, 2026
- PollenVax Subcutaneous Immunotherapy for Mugwort Pollen-Induced Allergic RhinitisNCT07563439 · Phase 2 · Kazakh National Agrarian University · starts May 1, 2026
- GRASS (Grass MATA MPL Real-world Assessment Study)NCT07412990 · Not reported · Allergy Therapeutics · starts Mar 11, 2026
- Clinical Study on TQH2722 Injection Combined With Background Therapy for Seasonal Allergic RhinitisNCT07398859 · Phase 2 · Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. · starts Mar 19, 2026
Approved 24 of 38
- Mometasone furoateGlucocorticoid receptor agonist
- Fluticasone propionateGlucocorticoid receptor agonist
- AzelastineHistamine H1 receptor antagonist
- DesloratadineHistamine H1 receptor antagonist
- Fluticasone furoateGlucocorticoid receptor agonist
- CiclesonideGlucocorticoid receptor agonist
- LoratadineHistamine H1 receptor antagonist
- CetirizineHistamine H1 receptor antagonist
- MontelukastCysteinyl leukotriene receptor 1 antagonist
- FexofenadineHistamine H1 receptor antagonist
- Beclomethasone dipropionateGlucocorticoid receptor agonist
- BudesonideGlucocorticoid receptor agonist
- OlopatadineHistamine H1 receptor antagonist
- LevocetirizineHistamine H1 receptor antagonist
- PseudoephedrineNorepinephrine transporter releasing agent
- DexchlorpheniramineHistamine H1 receptor antagonist
- PhenylephrineAdrenergic receptor alpha-1 agonist
- OxymetazolineAdrenergic receptor alpha agonist
- AtropineMuscarinic acetylcholine receptor M3 antagonist
- ChlorpheniramineHistamine H1 receptor antagonist
- DiphenhydramineHistamine H1 receptor antagonist
- Triamcinolone acetonideGlucocorticoid receptor agonist
- EpinephrineAdrenergic receptor agonist
- PromethazineHistamine H1 receptor antagonist
Phase 3 12 of 14
- BilastineHistamine H1 receptor inverse agonist
- OmalizumabIg epsilon chain C region inhibitor
- EpinastineHistamine H1 receptor antagonist
- SetipiprantG protein-coupled receptor 44 antagonist
- Lactobacillus acidophilusProbiotic
- Stapokibart
- AlbuterolBeta-2 adrenergic receptor agonist
- TriamcinoloneGlucocorticoid receptor agonist
- PranlukastCysteinyl leukotriene receptor 1 antagonist
- Bifidobacterium spp.Probiotic
- Resveratrol
- Freneslerbart
Phase 2 12 of 23
- GSK-256066Phosphodiesterase 4 inhibitor
- BepotastineHistamine H1 receptor antagonist
- AZD-8848Toll-like receptor 7 agonist
- LevocabastineHistamine H1 receptor antagonist
- HistamineHistamine H1 receptor agonist
- TimapiprantG protein-coupled receptor 44 antagonist
- GSK-1004723Histamine H3 receptor antagonist
- OxybutyninMuscarinic acetylcholine receptor M3 antagonist
- PF-03654746Histamine H3 receptor antagonist
- PF-03654764Histamine H3 receptor antagonist
- FevipiprantG protein-coupled receptor 44 antagonist
- QAV680G protein-coupled receptor 44 antagonist
Phase 1 or earlier 12 of 13
- IbuprofenCyclooxygenase inhibitor
- IdelalisibPI3-kinase p110-delta subunit inhibitor
- KetorolacCyclooxygenase inhibitor
- Phenol
- DoxylamineHistamine H1 receptor antagonist
- ImatinibTyrosine-protein kinase ABL inhibitor
- CAL-263PI3-kinase p110-delta subunit inhibitor
- EsketamineGlutamate [NMDA] receptor negative allosteric modulator
- QuilizumabIg epsilon chain C region inhibitor
- MEDI-4212Ig epsilon chain C region inhibitor
- VotucalisHistamine sequestering agent
- Syrup
How its trials ended
375 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 115 whose ending is known, 80% met their primary endpoint, 10% missed it and 10% stopped early.
- Completed, result not reported22660%
- Met its primary endpoint9225%
- Ongoing195%
- Status unknown154%
- Missed its primary endpoint113%
- Stopped: enrollment or feasibility72%
- Stopped: sponsor or business decision21%
- Stopped: other or unclear21%
- Stopped: safety1<1%
| Nov 13, 2026 | Follow-up to a phase 2 trial to evaluate the safety and immunological effects of short-course DM-101PX in adults with birch pollen-induced allergic rhinitis or…DM-101PX | Desentum Oy | Pending |
| Dec 31, 2025 | A randomized, double-blind, placebo-controlled, environmental exposure unit trial of intranasal INI-2004 in subjects with ragweed-induced allergic rhinitisINI-2004 | Inimmune Corporation | Closed |
| Oct 23, 2025 | A phase 3, multicenter, randomized, double-blind, placebo controlled, parallel group study to evaluate the efficacy and safety of lebrikizumab in adult and…Lebrikizumab (LY3650150) / Azelastine | Eli Lilly | Ongoing |
| Aug 26, 2025 | A two-part, adaptive, double-blind, randomized, placebo-controlled, study to assess the appropriate dose and the appropriate dosing frequency of aldp 001 in…Alcaftadine (ALDP001) | Alixer Nexgen Therapeutics Ltd | Closed |
| May 24, 2023 | An open-label, single-dose, three-way crossover study to compare the pharmacokinetics of fixed-dose combination of mometasone + azelastine nasal spray to…Azelastine-mometasone / Azelastine / Mometasone | Sandoz | Closed |
| Nov 30, 2022 | A phase IIIb, single-center, double-blind, two-arms, placebo-controlled, randomized, parallel-group clinical trial to evaluate the efficacy and safety of 2-day…Fexofenadine (M016455) | Opella Healthcare Group SAS | Closed |
| Jul 25, 2022 | A two-part randomized, double-blind, placebo-controlled study to assess the efficacy of the anti-bet v 1 monoclonal antibodies to reduce allergic rhinitis and…REGN5713 / REGN5714 / REGN5715 | Regeneron | Closed |
| Mar 5, 2021 | Efficacy and safety of the sq tree sublingual immunotherapy tablet in children and adolescents (5 through 17 years of age) with moderate to severe allergic…Itulatek | ALK-Abelló | Closed |
| Dec 22, 2020 | A phase 3 randomized, double-blind, placebo-controlled study assessing the efficacy of anti-bet v 1 monoclonal antibodies to reduce symptoms of seasonal…REGN5713-5714-5715 | Regeneron | Closed |
| Oct 26, 2018 | A randomized, double-blind, placebo controlled study to assess the safety and tolerability of HAL-MRE1 subcutaneous immunotherapy in adult subjects with…HAL-MRE1 | Hal Allergy BV | Pending |
| Authorised | Medicine | Holder | EPAR |
|---|---|---|---|
| Jul 30, 2007 | AerinazeDesloratadine; pseudoephedrine | Organon N.V. | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA